Establishing the role of tigecycline in an era of antimicrobial resistance (Q37291328)

19 August 2017

1 reference

title

Establishing the role of tigecycline in an era of antimicrobial resistance (English)

1 reference

19 August 2017

antimicrobial resistance

1 reference

2

Debra A Goff

1 reference

19 August 2017

Jason J Schafer

1

1 reference

19 August 2017

1 October 2008

1 reference

Expert Review of Anti-infective Therapy

19 August 2017

1 reference

19 August 2017

6

1 reference

19 August 2017

5

1 reference

19 August 2017

557-567

1 reference

The pharmacokinetic and pharmacodynamic profile of tigecycline

19 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Tigecycline: a new glycylcycline for treatment of serious infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

The glycylcyclines: a comparative review with the tetracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

In vitro activity of tigecycline against Bacteroides species

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

In vitro activity of tigecycline against metallo-beta-lactamase-producing Enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Rapid development of Acinetobacter baumannii resistance to tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-component system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Multidrug-resistant Acinetobacter baumannii osteomyelitis from Iraq

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Multidrug-resistant Klebsiella pneumoniae mediastinitis safely and effectively treated with prolonged administration of tigecycline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Meticillin-resistant Staphylococcus aureus hepatic abscess treated with tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.557

21 January 2018

Identifiers

DOI

10.1586/14787210.6.5.557

1 reference

release_5iirawtdcfdstebdp7jdjgsn4m

19 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5iirawtdcfdstebdp7jdjgsn4m

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

18847395

1 reference

PubMed ID

18847395